Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -1.33% 185.00 175.00 195.00 187.50 185.00 187.50 13,668 16:26:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -17.8 -35.3 - 102

Faron Pharmaceuticals Oy Share Discussion Threads

Showing 1576 to 1600 of 1600 messages
Chat Pages: 64  63  62  61  60  59  58  57  56  55  54  53  Older
DateSubjectAuthorDiscuss
15/6/2022
20:48
I wonder if they now know who will respond to treatment before the drug is given. Also, if the response rate would be higher if given to less ill patients whose immune system can still be stimulated into action. Time will tell. Notwithstanding, with my limited understanding of the science, the results look impressive.
hashertu
25/4/2022
14:58
New job ad from Faron. Director of Finance. According to job description: " The goal is to elevate and develop the processes to level accepted by the SEC in case of a potential US listing".Key responsibilities-Lead PCAOB uplift in preparation for a potential US listing together with external advisors-Be part of the "IPO" teamhttps://www.faron.com/sites/default/files/Director%20of%20Finance%20www-sivut%20250422.pdf
share23
23/4/2022
18:56
Faron latest presentation. CFO mentions that they have hired new VP of investor relations to New York and that they are making Faron Wallstreet ready. Are they getting ready for an IPO to Nasdaq, New York? (around 4:00 minutes)Additionally CEO talks about potential licensing deal for Bexmarilimab and refers to other deals that have been made in the area which are billion-dollar milestone deals. CEO also says after mentioning the billion dollar deals: Happy to say there are number of companies discussing with us (around 19:00 minutes).Can't believe this company is so under the radar with so low share price.https://faron.videosync.fi/agm_2022_presentation_ceo_and_cfo
share23
23/2/2022
12:29
Worth adding here at these levels IMHO, and have done 😀. Looking forward to hearing the webcast. DL
davidlloyd
23/2/2022
10:34
It does sound promising. But trying to make sense of the statistics is a step too far, for me, without more explanation.
hashertu
23/2/2022
07:45
Nice RNS Faron!
raldo
10/12/2021
10:12
Yesterday's news. Another small step in the right direction.
hashertu
23/9/2021
11:44
Faron seems to have busy time ahead:https://www.g20innovationleague.com/azienda/faron-pharmaceuticals-oyhttps://macrophage-directed-therapies.com/speaker/maija-hollmen/https://macrophage-directed-therapies.com/speaker/juho-jalkanen/
share23
21/9/2021
19:12
Updated corporate presentation from Faron. Lots of interesting reeding.https://www.faron.com/sites/default/files/Corporate%20Deck%20SEP%202021.pdf
share23
18/9/2021
13:09
https://dailyreporter.esmo.org/esmo-congress-2021/drug-development/bexmarilimab-monotherapy-shows-promising-anti-tumour-activity-in-advanced-solid-tumours
share23
17/9/2021
12:08
"The efficacy and survival data are particularly compelling when you consider the late-stage, treatment-refractory disease patient population and inclusion of nonimmunogenic cold tumors in the trial." A fairly bullish statement from the principal investigator! Again, no nasties coming out of the woodwork. I wonder when they hope to move to earlier stage patients who (probably) have less compromised immune systes.
hashertu
17/9/2021
08:23
Breast cancer seems to be new responder group with 4/10. According to WHO 2.3 million new breast cancer cases was detected in 2020. About 80% of these seems to be ER+. Huge market.https://www.who.int/news-room/fact-sheets/detail/breast-cancerhttps://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive
share23
17/9/2021
07:13
On 1st pass data looks good Landmark OS analysis of Part I/II patients who received three courses of treatment and had their scheduled tumor imaging at cycle four (n=91) estimated that 83% of patients achieving disease control rate (DCR) status were alive at six months after the landmark (approximately 240 days from initiation of treatment) compared to 29% of non-DCR patients. The most significant disease control rate (DCR) among Part II cohorts was observed in cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%), hepatocellular carcinoma (40%) and breast cancer (40%) patients.
waterloo01
26/8/2021
10:08
Very much, steady as she goes. No nasties, so far, which is good. The MATINS trial expansion is encouraging. Possible interesting data to be presented in September.
hashertu
14/6/2021
08:38
I can't claim to know what the patent entails, but if the USA grant it, then I suspect the RoW will follow suit. Let's hope it works well in vivo.
hashertu
03/6/2021
23:23
https://www.utu.fi/en/news/press-release/novel-antibody-drug-wakes-up-the-bodys-defense-system-in-advanced-stage-cancer
dan1nat1
18/5/2021
13:46
Latest Proactive interview https://youtu.be/KTcfr56hxMY
dan1nat1
22/3/2021
08:47
So phase 2 to be released next quarter, wants the cash position like for phase 3, I see no mention of the approximate date
milliecusto
22/3/2021
08:07
Outstanding news from Faron today, how long will it keep drifting under the radar...?
raldo
26/1/2021
22:18
Proactive Q&Ahttps://www.proactiveinvestors.co.uk/companies/news/939380/faron-pharmaceuticals-shareholder-qa-939380.html
dan1nat1
26/1/2021
09:31
Indeed. Faron must have presented a strong case for the FDA to accept that corticosteroids MIGHT be having an adverse reaction. I have also wondered, in the past, whether Immupharma/Lupuzor was failing for a similar reason. As the study is not blinded, will we get an update after 70 patients/14 days plus analysis time?
hashertu
26/1/2021
07:56
FDA approval, this month has been very news rich indeed.
bwgs
22/1/2021
14:11
Definitely DanAmazing potential in Q1 and by end of Q2.Interviewer said she would hold Markku to his word ;)
cwebb07
21/1/2021
23:23
https://www.youtube.com/watch?v=NVpVcsRxO6oWatch from 36 mins, a fantastic presentation that really does make us look cheap!
dan1nat1
20/1/2021
11:31
This morning's RNS prompted me to do some reading about T cells. Fascinating to see how complex the immune process is and a reminder of how little I know about biology. My investment here is based on trust and belief in Markku.
hashertu
Chat Pages: 64  63  62  61  60  59  58  57  56  55  54  53  Older
ADVFN Advertorial
Your Recent History
LSE
FARN
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220930 01:10:13